Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 10/24/25
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common StockGlobeNewsWire • 09/30/25
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary EndpointGlobeNewsWire • 09/30/25
Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/25
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyGlobeNewsWire • 06/26/25
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?Zacks Investment Research • 06/25/25
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025GlobeNewsWire • 06/16/25
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge UpsideBenzinga • 03/11/25
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/03/25
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025GlobeNewsWire • 02/24/25
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual MeetingGlobeNewsWire • 02/03/25
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDRGlobeNewsWire • 01/14/25
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/10/24